Your browser doesn't support javascript.
loading
Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates.
Gunn, Bronwyn M; McNamara, Ryan P; Wood, Lianna; Taylor, Sabian; Devadhasan, Anush; Guo, Wenyu; Das, Jishnu; Nilsson, Avlant; Shurtleff, Amy; Dubey, Sheri; Eichberg, Michael; Suscovich, Todd J; Saphire, Erica Ollmann; Lauffenburger, Douglas; Coller, Beth-Ann; Simon, Jakub K; Alter, Galit.
Afiliação
  • Gunn BM; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • McNamara RP; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA. Electronic address: ragonsystemserology@mgh.harvard.edu.
  • Wood L; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Division of Gastroenterology, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
  • Taylor S; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Devadhasan A; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Guo W; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Das J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Nilsson A; Division of Gastroenterology, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
  • Shurtleff A; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
  • Dubey S; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Eichberg M; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Suscovich TJ; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Saphire EO; La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Lauffenburger D; Division of Gastroenterology, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
  • Coller BA; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Simon JK; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Alter G; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Cell Rep ; 42(4): 112402, 2023 04 25.
Article em En | MEDLINE | ID: mdl-37061918
ABSTRACT
The 2013 Ebola epidemic in Central and West Africa heralded the emergence of wide-spread, highly pathogenic viruses. The successful recombinant vector vaccine against Ebola (rVSVΔG-ZEBOV-GP) will limit future outbreaks, but identifying mechanisms of protection is essential to protect the most vulnerable. Vaccine-induced antibodies are key determinants of vaccine efficacy, yet the mechanism by which vaccine-induced antibodies prevent Ebola infection remains elusive. Here, we exploit a break in long-term vaccine efficacy in non-human primates to identify predictors of protection. Using unbiased humoral profiling that captures neutralization and Fc-mediated functions, we find that antibodies specific for soluble glycoprotein (sGP) drive neutrophil-mediated phagocytosis and predict vaccine-mediated protection. Similarly, we show that protective sGP-specific monoclonal antibodies have elevated neutrophil-mediated phagocytic activity compared with non-protective antibodies, highlighting the importance of sGP in vaccine protection and monoclonal antibody therapeutics against Ebola virus.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença pelo Vírus Ebola / Vacinas contra Ebola / Ebolavirus Tipo de estudo: Risk_factors_studies Limite: Animals Idioma: En Revista: Cell Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença pelo Vírus Ebola / Vacinas contra Ebola / Ebolavirus Tipo de estudo: Risk_factors_studies Limite: Animals Idioma: En Revista: Cell Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos